NCT05059158 · RECRUITING
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
This is an observational brain-imaging study, not a drug test. Researchers use PET scans to look at how the brain clears amyloid, the sticky protein linked to Alzheimer's. They are studying the brain's drainage routes, including the blood-brain barrier and the glymphatic system. Participants have normal thinking, mild memory impairment, or mild Alzheimer's. No phase is listed.
You may qualify if
- Diagnosis of amnestic MCI or AD dementia or clinical normal
- Able to provide written informed consent
- Unchanged pharmacotherapy within 4 days prior to the study specific assessments
- Fluent in German
You're excluded if
- Unable to give informed consent or has a legal guardian
- Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
- Clinically relevant depression
- Acute suicidality
- Current alcohol, drug or medication abuse
- History of severe traumatic brain injury within 3 months prior to inclusion
- Structural lesions of the basal ganglia or brain stem
- Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
- Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension
- Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication
- Renal failure > stage 3 (GFR \< 30 mL/min)
- Pregnancy
- Unresolved malignancies within two years prior to inclusion
- Severe current infections or other chronic or systemic disorders
- Other circumstances which preclude participation based on the investigator's judgement
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-04